Mary J Thomson1, Anna S F Lok2, Elliot B Tapper2,3,4. 1. Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN. 2. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI. 3. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI. 4. Veterans Affairs Hospital, Ann Arbor, MI.
Abstract
BACKGROUND AND AIMS: Patients with decompensated cirrhosis are prescribed numerous medications. Data are limited as to whether patients are receiving medications they need and avoiding those they do not. We examined a large national claims database (2010-2015) to characterize the complete medication profile as well as the factors associated with appropriate and potentially inappropriate medication use in 12,621 patients with decompensated cirrhosis. APPROACH AND RESULTS: Clinical guidelines and existing literature were used to determine appropriate and potentially inappropriate medications in decompensated cirrhosis. The total medication days' supply was calculated from pharmacy data and divided by the follow-up period for each decompensation. Ascites was the most common (86.5%), followed by hepatic encephalopathy (HE; 37.8%), variceal bleeding (VB; 17.5%), hepatorenal syndrome (6.3%), and spontaneous bacterial peritonitis (SBP; 6.1%). For patients with ascites, 55.8% filled a diuretic. For patients with HE, 32.4% and 63.3% filled rifaximin and lactulose, respectively. After VB, 60.3% of patients filled a nonselective beta blocker, and after an episode of SBP, 48.0% of patients filled an antibiotic for prophylaxis. The minority (4.5%-17.3%) had enough medication to cover >50% follow-up days. Potentially inappropriate medication use was common: 53.2% filled an opiate, 46.0% proton pump inhibitors, 14.2% benzodiazepines, and 10.1% nonsteroidal anti-inflammatory drugs. Disease severity markers were associated with more appropriate mediation use but not consistently associated with less inappropriate medication use. CONCLUSIONS: Patients with decompensated cirrhosis are not filling indicated medications as often or as long as is recommended and are also filling medications that are potentially harmful. Future steps include integrating pharmacy records with medical records to obtain a complete medication list and counseling on medication use with patients at each visit.
BACKGROUND AND AIMS: Patients with decompensated cirrhosis are prescribed numerous medications. Data are limited as to whether patients are receiving medications they need and avoiding those they do not. We examined a large national claims database (2010-2015) to characterize the complete medication profile as well as the factors associated with appropriate and potentially inappropriate medication use in 12,621 patients with decompensated cirrhosis. APPROACH AND RESULTS: Clinical guidelines and existing literature were used to determine appropriate and potentially inappropriate medications in decompensated cirrhosis. The total medication days' supply was calculated from pharmacy data and divided by the follow-up period for each decompensation. Ascites was the most common (86.5%), followed by hepatic encephalopathy (HE; 37.8%), variceal bleeding (VB; 17.5%), hepatorenal syndrome (6.3%), and spontaneous bacterial peritonitis (SBP; 6.1%). For patients with ascites, 55.8% filled a diuretic. For patients with HE, 32.4% and 63.3% filled rifaximin and lactulose, respectively. After VB, 60.3% of patients filled a nonselective beta blocker, and after an episode of SBP, 48.0% of patients filled an antibiotic for prophylaxis. The minority (4.5%-17.3%) had enough medication to cover >50% follow-up days. Potentially inappropriate medication use was common: 53.2% filled an opiate, 46.0% proton pump inhibitors, 14.2% benzodiazepines, and 10.1% nonsteroidal anti-inflammatory drugs. Disease severity markers were associated with more appropriate mediation use but not consistently associated with less inappropriate medication use. CONCLUSIONS: Patients with decompensated cirrhosis are not filling indicated medications as often or as long as is recommended and are also filling medications that are potentially harmful. Future steps include integrating pharmacy records with medical records to obtain a complete medication list and counseling on medication use with patients at each visit.
Authors: Mattias Mandorfer; Simona Bota; Philipp Schwabl; Theresa Bucsics; Nikolaus Pfisterer; Matthias Kruzik; Michael Hagmann; Alexander Blacky; Arnulf Ferlitsch; Wolfgang Sieghart; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: Gastroenterology Date: 2014-03-12 Impact factor: 22.682
Authors: Fasiha Kanwal; Elliot B Tapper; Chanda Ho; Sumeet K Asrani; Nadia Ovchinsky; John Poterucha; Avegail Flores; Victor Ankoma-Sey; Bruce Luxon; Michael Volk Journal: Hepatology Date: 2019-03-12 Impact factor: 17.425
Authors: Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy Journal: Aliment Pharmacol Ther Date: 2019-04-29 Impact factor: 8.171
Authors: Jasmohan S Bajaj; Ashwin N Ananthakrishnan; Muhammad Hafeezullah; Yelena Zadvornova; Alexis Dye; Emily L McGinley; Kia Saeian; Douglas Heuman; Arun J Sanyal; Raymond G Hoffmann Journal: Am J Gastroenterol Date: 2009-10-20 Impact factor: 10.864
Authors: Kelly L Hayward; Preya J Patel; Patricia C Valery; Leigh U Horsfall; Catherine Y Li; Penny L Wright; Caroline J Tallis; Katherine A Stuart; Katharine M Irvine; W Neil Cottrell; Jennifer H Martin; Elizabeth E Powell Journal: Hepatol Commun Date: 2019-03-18
Authors: Kelly L Hayward; Patricia C Valery; W Neil Cottrell; Katharine M Irvine; Leigh U Horsfall; Caroline J Tallis; Veronique S Chachay; Brittany J Ruffin; Jennifer H Martin; Elizabeth E Powell Journal: BMC Gastroenterol Date: 2016-09-13 Impact factor: 3.067
Authors: Kelly L Hayward; Patricia C Valery; Preya J Patel; Catherine Li; Leigh U Horsfall; Penny L Wright; Caroline J Tallis; Katherine A Stuart; Michael David; Katharine M Irvine; Neil Cottrell; Jennifer H Martin; Elizabeth E Powell Journal: Pharmaceuticals (Basel) Date: 2021-11-23